Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGEATB)

• Drug Name: Siltuximab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Anemia	3A00-3A9Z	Approved	[1]
Idiopathic multicentric Castlemans disease	2A81.Y	Approved	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[3]
Multiple myeloma	2A83	Phase 2	[4]
Castleman's disease	4B2Y	Investigative	[5]

• Cross-matching ID: TTD Drug ID: DMGEATB

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-6 (IL6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sirukumab	DMK8AQP	Cutaneous lupus erythematosus	EB5Z	Phase 3	[8]
Olokizumab	DM4Z9QI	Rheumatoid arthritis	FA20	Phase 3	[9]
Ziltivekimab	DME841B	Heart failure	BD10-BD13	Phase 3	[10]
RG6179	DMO1VP9	uveitic macular edema	9B78	Phase 3	[11]
PF-04236921	DM826SW	Crohn disease	DD70	Phase 2	[8]
Clazakizumab	DM6ZOUV	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2 Trial	[8]
CDP-6038	DM3YB2C	Rheumatoid arthritis	FA20	Phase 2	[12]
ALD-518	DMPWSBL	Psoriatic arthritis	FA21	Phase 2	[12]
YSIL6	DM0K8U7	Crohn disease	DD70	Phase 2	[13]
Gerilimzumab	DMA9UX2	Rheumatoid arthritis	FA20	Phase 1	[8]

Drug(s) Targeting HUMAN interleukin 6 (IL6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sirukumab	DMK8AQP	Cutaneous lupus erythematosus	EB5Z	Phase 3	[14]
Olokizumab	DM4Z9QI	Rheumatoid arthritis	FA20	Phase 3	[15]
Clazakizumab	DM6ZOUV	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2 Trial	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-6 (IL6)	TTT1V78	IL6_HUMAN	Not Available	[6]
HUMAN interleukin 6 (IL6)	TTJH4Y5	IL6_HUMAN	Inhibitor	[7]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7396).
• [2] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 125496.
• [3] ClinicalTrials.gov (NCT04330638) Treatment of COVID-19 Patients With Anti-interleukin Drugs. U.S. National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014 Aug;15(9):966-74.
• [6] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [7] Siltuximab. In: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. 2018 Dec 3.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014 September; 73(9): 1607-1615.
• [10] IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 May 29;397(10289):2060-2069.
• [11] Clinical pipeline report, company report or official report of Roche
• [12] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020380)
• [14] Sirukumab: A Potential Treatment for Mood Disorders Adv Ther. 2017 Jan;34(1):78-90.
• [15] Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014 May-Jun;6(3):774-82.
• [16] Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS) J Autoimmun. 2020 Apr 10:102452.